Logitech International: Logitech Grows 76% for Fiscal Year 2021, Q4 Revenue Doubles
Company Raises FY 2022 Guidance, Share Buyback Authorization Raised to $1 Billion
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full year of Fiscal Year 2021, ended March 31, 2021.
For Fiscal Year 2021:
Sales were Logitech s highest ever at $5.25 billion, up 76 percent in US dollars and 74 percent in constant currency compared to the prior year.
GAAP operating income grew 315 percent to $1.15 billion, compared to $276 million a year ago. GAAP earnings per share (EPS) grew 107 percent to $5.51, compared to $2.66 a year ago.
Non-GAAP operating income grew 229 percent to $1.27 billion, compared to $387 million a year ago. Non-GAAP EPS grew 199 percent to $6.42, compared to $2.15 a year ago.
5 hours ago
Company Raises FY 2022 Guidance, Share Buyback Authorization Raised to $1 Billion
LAUSANNE, Switzerland & NEWARK, Calif.–(BUSINESS WIRE)–$LOGI–Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full year of Fiscal Year 2021, ended March 31, 2021.
For Fiscal Year 2021:
Sales were Logitech’s highest ever at $5.25 billion, up 76 percent in US dollars and 74 percent in constant currency compared to the prior year.
GAAP operating income grew 315 percent to $1.15 billion, compared to $276 million a year ago. GAAP earnings per share (EPS) grew 107 percent to $5.51, compared to $2.66 a year ago.
Non-GAAP operating income grew 229 percent to $1.27 billion, compared to $387 million a year ago. Non-GAAP EPS grew 199 percent to $6.42, compared to $2.15 a year ago.
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO-GI 2021
Initiated new combination study evaluating NBTXR3 activated by radiation in combination with chemotherapy in esophageal cancer and reported new preclinical data in immunotherapy at AACR RSM 2021, providing further support for radioenhancer NBTXR3 as a therapeutic combination-agnostic that could prime adaptive immune response for local and systemic control
New collaboration agreement signed by subsidiary Curadigm with Sanofi evaluating novel Nanoprimer technology in gene therapy
Cash, cash equivalents, and short-term investments were €107.1 million at March 31, 2021, continuing to support robust development plans into the second quarter of 2023
Share:
DBV Technologies to
Upcoming Investor Conferences
DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced its participation in the following upcoming virtual investor conferences in May 2021.
Kempen
Life Sciences Conference, May 5, 2021
Dr. Pharis Mohideen, Chief Medical Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.
Societe
Nice Conference, May 27, 2021
Daniel Tassé, Chief Executive Officer, and Sebastien Robitaille, Chief Financial Officer, will participate in virtual investor meetings.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the
San Antonio oil company Abraxas faces loan default, de-listing from Nasdaq market
FacebookTwitterEmail
People work on the Abraxas Petroleum Corporation frac spread in Atascosa County Texas on August 23, 2016.Carolyn Van Houten / Carolyn Van Houten
Troubles have followed oil and gas producer Abraxas Petroleum Corp. into 2021, and the San Antonio-based company could be kicked off the Nasdaq market this year.
In a document filed with the Securities and Exchange Commission last week, Abraxas said it is evaluating its options as $200 million in debt comes due and lenders have declared it in default.
Abraxas said investment banking firm Morgan Stanley terminated hedging contracts with the company as a result of Abraxas not paying its debt on one loan.